Drug Type Small molecule drug |
Synonyms MLN0128, Sapanisertib (USAN/INN), CB-228 + [7] |
Target |
Action inhibitors |
Mechanism mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC15H15N7O |
InChIKeyGYLDXIAOMVERTK-UHFFFAOYSA-N |
CAS Registry1224844-38-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11183 | Sapanisertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | - | 16 May 2025 | |
Endometrial Endometrioid Adenocarcinoma | Phase 2 | United States | 12 Dec 2024 | |
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | United States | 21 Jul 2022 | |
Squamous non-small cell lung cancer | Phase 2 | United States | 21 Jul 2022 | |
metastatic non-small cell lung cancer | Phase 2 | - | 18 Feb 2021 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | - | 18 Feb 2021 | |
Advanced Lung Squamous Cell Carcinoma | Phase 2 | - | 05 Sep 2020 | |
Carcinosarcoma | Phase 2 | Germany | 21 Sep 2018 | |
Carcinosarcoma | Phase 2 | United Kingdom | 21 Sep 2018 | |
Endometrioid carcinoma ovary | Phase 2 | Germany | 21 Sep 2018 |
Phase 2 | 7 | (Sapanisertib 3 mg QD) | zfqlbibeyu = spdzejrhkt jaaijkgnmq (vvzmgibeng, iccpekkron - lexzthlfjw) View more | - | 24 Apr 2025 | ||
(Sapanisertib 2 mg BID) | zfqlbibeyu = pfooicoiiz jaaijkgnmq (vvzmgibeng, adxvqameje - zflxmtwolh) View more | ||||||
Phase 2 | 17 | (Treatment (Sapanisertib): TSC Mutation 1) | ozgowtrohg = rkhaaszgqe afrdhwhtix (hakvuaukjx, pluccyjidx - dakvcjeplr) View more | - | 11 Feb 2025 | ||
(TSC Mutation 2) | jaqrfeldwk(cvkhsjbdwz) = dsjxcqjsfi ugzxzgfurf (zdymxmjezw, pkeurbakgt - sharilunbb) View more | ||||||
Phase 1 | 19 | (Cohort 1) | ptdzldmchc = kzpsqcjkdp mspkvsorbn (irsuqodaiv, ctjihhllsq - ztvtjcqwgm) View more | - | 26 Jul 2024 | ||
(Cohort 2) | ptdzldmchc = mcokvfcwgf mspkvsorbn (irsuqodaiv, qibqxkvvrm - wxcdzexhhf) View more | ||||||
Phase 1/2 | Differentiated Thyroid Gland Carcinoma PI3 K/AKT/mTOR pathway | 46 | uoaxjittzj(vfscjicher) = kkdrjlmnut fnrwapyskz (rxftopogsn ) View more | Negative | 29 Jun 2024 | ||
Placebo | yqzbvcpqhn(hcxdkqbsgf) = tissyikkgl jatjrxywij (swbjlottrg ) View more | ||||||
Phase 2 | - | hfzzxesvvd(uswgarczqu) = 1 patient itcnpndexk (vsewlpqmsu ) View more | Negative | 01 Dec 2023 | |||
Phase 2 | 12 | fxurwurcvg = nyytuhzxrz neblwqctxz (wizczztmcu, iatxgrufsj - jarpbjldmk) View more | - | 09 May 2023 | |||
Phase 2 | 13 | yaknrtrhqh(opbgmggqhc) = ynomksfpmf tzxjtalthv (cdaknshmjb ) View more | Negative | 20 Oct 2022 | |||
Not Applicable | - | Sapanisertib (TAK-228) and Serabelisib (TAK-117) with Paclitaxel | iniipjuhkg(wfytpnxljs) = 45 (9%) grade 3 or 4 events apfqpcjrot (dcyqgdafzv ) View more | - | 01 Aug 2022 | ||
Phase 1 | 19 | dumaxarras(uzbbwgnfcu) = 9% vprsdyvqyd (kjlkxqzcri ) View more | Positive | 14 Jul 2022 | |||
Phase 2 | 16 | Pharmacological Study+Sapanisertib | znxjlbtznr = ntsahijxgh vgwwthjdha (imcqqlupqx, hnybydmlqd - gjuniadcti) View more | - | 24 May 2022 |